ArticleHematology, transfusion and cell therapy2026
Rapid genomic analysis for early identification of complement abnormalities in adults with transplant-associated thrombotic microangiopathy.
Article in Hematology, transfusion and cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransplant-associated thrombotic microangiopathy is a severe and often fatal complication of allogeneic hematopoietic cell transplantation; early identification of the involved mechanisms may enable timely therapy. STUDY
designAdult recipients of allogeneic hematopoietic cell transplantation (n = 195) were studied in the early post-transplant period. The recent harmonizing criteria from the world's leading blood and marrow transplant societies, such as ≥4 of 7 specific clinical/laboratory features for thrombotic microangiopathy diagnosis were applied. Plasma levels of sC5b-9, a marker of complement activation, was measured by an enzyme-linked immunosorbent assay and complement-related genes in blood cells were evaluated by both rapid genomic analyses using nanopore sequencing and conventional methods (targeted next generation sequencing and multiplex ligation-dependent probe amplification assay).
resultsTen patients who met ≥4 criteria (confirmed transplant-associated thrombotic microangiopathy) had high 1-year non-relapse mortality (60%) and high complement activation. In this group, plasma levels of sC5b-9 were higher than in patients without confirmed disease (p-value = 0.04) and normal controls (p-value <0.001). At the same time (after full chimerism), they showed seven rare variants of complement related genes (minor allele frequency <0.03). Rapid genomic analysis identified these alterations with complete concordance to conventional methods.
conclusionsThese results support the utility of applying harmonized criteria for early diagnosis of transplant-associated thrombotic microangiopathy and performing rapid genomic analysis with nanopore sequencing for the identification of variants in complement-related genes within 72h. Future studies on larger cohorts could explore the integration of rapid genomic analysis in this patient population and potentially for screening donors whose cells may carry genetic alterations for real-time clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.